JERSEY CITY, N.J., Sept. 4, 2019 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ:SCYX), a biotechnology company delivering innovative
therapies for difficult-to-treat and often life-threatening
infections, today announced that the Company will present in the
following investor conferences:
- The H.C. Wainwright Global Investment Conference at the Lotte
New York Palace Hotel in New York
City on Monday, September 9,
2019 at 2:10 p.m. ET.
- The Ladenburg Thalmann Healthcare Conference at the Sofitel New
York in New York City on
Tuesday, September 24, 2019 at
1:30 p.m. ET.
Live webcasts of the presentations will be available on the
Investors section of the Company's website: www.scynexis.com.
Replays of the presentations will be available approximately two
hours after each event and will be available for two weeks
following each presentation.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a
biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often
life-threatening infections by developing innovative therapies. The
SCYNEXIS team has extensive experience in the life sciences
industry, having discovered and developed more than 30 innovative
medicines over a broad range of therapeutic areas. SCYNEXIS's lead
product candidate, ibrexafungerp (formerly known as SCY-078), is a
novel IV/oral antifungal agent in Phase 3 clinical and preclinical
development for the treatment of multiple serious and
life-threatening invasive fungal infections caused
by Candida, Aspergillus and Pneumocystis
species. For more information, visit www.scynexis.com.
CONTACT:
Investor Relations
Heather
Savelle
Argot Partners
Tel: 212-600-1902
heather@argotpartners.com
Media Relations
George E.
MacDougall
MacDougall
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-inc-to-participate-in-two-upcoming-investor-conferences-300911120.html
SOURCE SCYNEXIS, Inc.